- Home
- CDP vs VCYT Comparison
CDP vs VCYT Comparison
Compare CDP & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDP
- VCYT
- Stock Information
- Founded
- CDP 1988
- VCYT 2006
- Country
- CDP United States
- VCYT United States
- Employees
- CDP N/A
- VCYT N/A
- Industry
- CDP Real Estate Investment Trusts
- VCYT Medical Specialities
- Sector
- CDP Real Estate
- VCYT Health Care
- Exchange
- CDP Nasdaq
- VCYT Nasdaq
- Market Cap
- CDP 3.5B
- VCYT 2.8B
- IPO Year
- CDP N/A
- VCYT 2013
- Fundamental
- Price
- CDP $28.47
- VCYT $36.80
- Analyst Decision
- CDP Buy
- VCYT Buy
- Analyst Count
- CDP 8
- VCYT 10
- Target Price
- CDP $33.50
- VCYT $40.40
- AVG Volume (30 Days)
- CDP 643.3K
- VCYT 788.0K
- Earning Date
- CDP 10-30-2025
- VCYT 11-04-2025
- Dividend Yield
- CDP 4.28%
- VCYT N/A
- EPS Growth
- CDP N/A
- VCYT N/A
- EPS
- CDP 1.27
- VCYT 0.34
- Revenue
- CDP $751,457,000.00
- VCYT $479,129,000.00
- Revenue This Year
- CDP N/A
- VCYT $14.48
- Revenue Next Year
- CDP $5.46
- VCYT $9.79
- P/E Ratio
- CDP $22.41
- VCYT $109.69
- Revenue Growth
- CDP 3.13
- VCYT 19.91
- 52 Week Low
- CDP $23.92
- VCYT $22.61
- 52 Week High
- CDP $34.22
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- CDP 48.32
- VCYT 62.00
- Support Level
- CDP $28.00
- VCYT $34.38
- Resistance Level
- CDP $28.61
- VCYT $37.07
- Average True Range (ATR)
- CDP 0.45
- VCYT 1.23
- MACD
- CDP 0.04
- VCYT -0.06
- Stochastic Oscillator
- CDP 74.19
- VCYT 90.96
About CDP COPT Defense Properties of Beneficial Interest
COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.